GLP-1 receptor agonists and adverse outcomes in patients with type 2 diabetes and chronic viral hepatitis.
Background/Aims Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a novel class of anti-diabetic drugs that can treat obesity and type 2 diabetes (T2D). T2D and chronic viral hepatitis (CVH) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed t...